clinical trial · NCT07539090
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
Deciphera Pharmaceuticals, LLC·phase1·recruiting·n = 24
Healthy ParticipantsVimseltinibCombined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
brief summary
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.
started
Jun 5, 2026
primary completion
Aug 1, 2026
completion
Aug 1, 2026
last updated
Jun 17, 2026
official title
A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) in Healthy Female Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol